摘要
背景与目的:近来有研究报道,在激素难治性前列腺癌(hormonerefractoryprostatecarcinoma,HRPC)中发现有雄激素受体(androgenreceptor,AR)基因扩增,并提出AR基因扩增可能是导致激素治疗失败的一个新的分子机制。本研究拟对前列腺癌在激素治疗前和治疗失败后的AR蛋白表达作定量测定,进一步探讨AR表达与HRPC发生的关系。方法:采用放射配体结合分析方法测定28例晚期前列腺癌患者在激素治疗前以及治疗失败后原发癌组织中的AR蛋白含量。结果:28例前列腺癌在治疗前、后癌组织中的AR蛋白平均水平分别为(390.0±204.1)和(690.4±444.0)fmol/mgProtein,两者间差异有显著性(P<0.001)。其中10例在治疗后12个月内复发,其AR蛋白平均水平在治疗前、后分别为(398.2±199.5)和(448.2±274.1)fmol/mgProtein两者间差异无显著性(P>0.20),其余18例的AR蛋白平均水平在治疗前、后分别为(386.4±212.3)和(824.9±468.6)fmol/mgProtein,两者间差异有显著性(P<0.001)。结论:AR蛋白水平升高可能是前列腺癌对激素治疗不敏感的原因之一。
BACKGROUND &OBJECTIVE:It was reported that androg en receptor (AR)g ene amplification was found in horm one refractory prostate(HRPC)and it has been thoug ht to be a possibl e molecular mechanism for the treatment failure.In this article,the expression of AR protein before a nd after hormone therapy was examined quantitatively in order to further clarify the relationship between AR expression and the g enesis of HRPC.METHODS :AR protein content was determined usin g radiolig and binding assay before a nd after hormone therapy in 28patients with a dvanced prostate cancer.RESULTS :The averag e levels of AR protein before a nd after hormone therapy were 390.0±204.1fmol /mg protein and 690.4±444.0fmol /mg protein,respectively(P<0.001).In 10patients whose diseases recur red in 12months after therapy,the mean levels of AR protein before and a fter therapy were 398.2±199.5fmol /mg protein and 448.2±274.1fmol /mg pro tein,respectively(P>0.20).In other 18patients with response duration more than 12months,the mean levels of AR protein before and after therapy wer e 386.4±212.3fmol /mg protein and824.9±468.6fmol /mg protein,respe ctively(P<0.001).CONCLUSION:The elevation of AR protein level was mos t likely to occur in the prostatic tum ors that had g ood response to hormone therapy and mig ht be involved in the g enesis o f HRPC.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2003年第1期95-97,共3页
Chinese Journal of Cancer
基金
国家自然科学基金项目(No.39270770)
